Hutchison China Meditech Ltd (HCM)

 

HCM Share PerformanceMore

52 week high5,920.00 09/01/18
52 week low2,069.50 01/03/17
52 week change 3,322.50 (149.83%)
4 week volume424,303 25/12/17

Latest NewsMore

Block listing Interim Review

RNS Number: 4748A Hutchison China Meditech Limited 29 December 2017 Blocklisting Six Monthly Return London: Friday, December 29, 201 7: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: Hutchison Chi...

Total Voting Rights

RNS Number: 4732A Hutchison China Meditech Limited 29 December 2017 Total Voting Rights London: Friday, December 29, 2017: For information purposes, Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at December 29, 2017, the issued share capital of Chi-Med consisted of 66,447,037 ordinary shares of US...

Chi-Med initiates fruquintinib clinical trials in US

Hutchison China MediTech has initiated the US phase I bridging clinical trial of fruquintinib. Fruquintinib is a highly sele...

Chi-Med Initiates Fruquintinib US Clinical Trials

RNS Number: 4687Z Hutchison China Meditech Limited 15 December 2017 Press Release Chi-Med Initiates Fruquintinib U.S. Clinical Trials London: Friday , December 15 , 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has initiated the United States Phase I bridging clinical trial of fruquintinib. Fruquintinib is a highly selective and potent...

Notification of Major Holdings

RNS Number: 2412V Hutchison China Meditech Limited 01 November 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached i...

NOTIFICATION OF MAJOR HOLDINGS

RNS Number: 2399V Hutchison China Meditech Limited 01 November 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Hutchison China MediTech Limited; Legal Entity Ide...

Chi-Med starts clinical trial of Inhibitor for gastric cancer patients

Hutchison China MediTech has initiated FRUTIGA, a pivotal phase III clinical trial of fruquintinib in combination with p...

FRUTIGA, a Phase III trial of Fruquintinib

RNS Number: 0641V Hutchison China Meditech Limited 31 October 2017 Press Release ChiMed Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line GastricCancer London: Tuesday , October 31 , 2017: Hutchison China MediTech Limited ("ChiMed") (AIM/Nasdaq: HCM) has initiated FRUTIGA , a pivotal Phase III clinical trial of fru quintinib in combin...

Latest discussion posts More

  • New article

    Nothing new but here's a nice new summary article from a U.S. Specialist Biotech IR Firm from ...
    10-Jan-2018
    David Global
  • Re: New Year

    I second that vote of thanks to David for his input.
    5-Jan-2018
    hopetown
  • New Year

    Belated Merry Christmas and Happy Near Year all. Thank you for your kind mention Sporty Investor, and do hope all who post here are well! Well, it's hard not to be with this ...
    4-Jan-2018
    Maru118

Users' HoldingsMore

Users who hold Hutchison China Meditech Ltd also hold..

Codes & Symbols

ISINKYG4672N1016
SymbolsHCM, LSE:HCM, HCM.L, HCM:LN, LON:HCM, XLON:HCM

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account